Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Schizophrenia News

Placenta Plays Role in Schizophrenia Risk
News
Placenta Plays Role in Schizophrenia Risk
09/21/2023
Jolynn Tumolo
The placenta, a key organ in supporting prenatal development, appears to play a more substantial role in the development of schizophrenia than previously recognized. 
The placenta, a key organ in supporting prenatal development, appears to play a more substantial role in the development of schizophrenia than previously recognized. 
The placenta, a key organ in...
09/21/2023
Psych Congress Network

Advertisement

Ulotaront Misses Primary Endpoint in Two Phase 3 Trials of Adults With Schizophrenia
News
Ulotaront Misses Primary Endpoint in 2 Phase 3 Trials of Adults With Schizophrenia
08/15/2023
Jolynn Tumolo
Ulotaront is a TAAR1 agonist with 5-HT1A agonist activity that was granted Breakthrough Therapy Designation by the FDA for the treatment of schizophrenia in May 2019.
Ulotaront is a TAAR1 agonist with 5-HT1A agonist activity that was granted Breakthrough Therapy Designation by the FDA for the treatment of schizophrenia in May 2019.
Ulotaront is a TAAR1 agonist...
08/15/2023
Psych Congress Network
CRT Effective Treatment for Aggression in Schizophrenia
News
CRT Effective Treatment for Aggression in Schizophrenia
06/27/2023
Evi Arthur
Cognitive Remediation Training was found to be an effective treatment for impulsive aggression for participants with schizophrenia with a history of aggression. Results were published in the journal Schizophrenia Research. 
Cognitive Remediation Training was found to be an effective treatment for impulsive aggression for participants with schizophrenia with a history of aggression. Results were published in the journal Schizophrenia Research. 
Cognitive Remediation Training...
06/27/2023
Psych Congress Network
News
Virtual Reality-Based Treatment Shows No Effect on Social Cognition in Patients With Schizophrenia
01/10/2023
Evi Arthur
The test program, DiSCoVR, indicated current SCT protocols are “unsuitable.”
The test program, DiSCoVR, indicated current SCT protocols are “unsuitable.”
The test program, DiSCoVR,...
01/10/2023
Psych Congress Network

Advertisement

News
Sleep Brainwave "Fingerprints" May Improve Understanding of Schizophrenia, Other Disorders
11/16/2022
Jolynn Tumolo
A new approach for characterizing the activity of the brain during sleep has revealed potential biomarkers in the brain activity of people with schizophrenia, according to a published in Sleep.
A new approach for characterizing the activity of the brain during sleep has revealed potential biomarkers in the brain activity of people with schizophrenia, according to a published in Sleep.
A new approach for...
11/16/2022
Psych Congress Network
News
Antipsychotic Efficacy Declines in Women Aged 45 and Older
11/12/2022
Evi Arthur
Researchers surmise this is due to lower estrogen levels.
Researchers surmise this is due to lower estrogen levels.
Researchers surmise this is due...
11/12/2022
Psych Congress Network
News
Dementia Risk More than Doubled in Patients With Schizophrenia
10/25/2022
Jolynn Tumolo
The risk of dementia in people with schizophrenia or other psychotic disorders is 2.52 times higher than the risk of those without a psychotic disorder, according to results from a new systematic review and meta-analysis published in...
The risk of dementia in people with schizophrenia or other psychotic disorders is 2.52 times higher than the risk of those without a psychotic disorder, according to results from a new systematic review and meta-analysis published in...
The risk of dementia in people...
10/25/2022
Psych Congress Network

Advertisement

News
Inflammation, Oxidation Associated With Aggression in Schizophrenia
10/12/2022
Systemic pro-inflammation, pro-oxidation, and leaky gut biomarkers were significantly higher in inpatients with schizophrenia with aggression than in inpatients with schizophrenia without aggression.
Systemic pro-inflammation, pro-oxidation, and leaky gut biomarkers were significantly higher in inpatients with schizophrenia with aggression than in inpatients with schizophrenia without aggression.
Systemic pro-inflammation,...
10/12/2022
Psych Congress Network
News
Neuropsychiatric Polygenic Risk Scores Associated With Psychiatric Diagnoses in Veterans
10/05/2022
Jolynn Tumolo
Polygenic risk scores for schizophrenia, bipolar disorder, and major depression were associated with receiving psychiatric diagnoses and were higher among patients with more hospitalizations, according to a study published in JAMA Psychiatry.
Polygenic risk scores for schizophrenia, bipolar disorder, and major depression were associated with receiving psychiatric diagnoses and were higher among patients with more hospitalizations, according to a study published in JAMA Psychiatry.
Polygenic risk scores for...
10/05/2022
Psych Congress Network
News
Continuing or Switching Antipsychotic Treatment Best Protects Against Relapse
09/28/2022
Jolynn Tumolo
In patients with schizophrenia-spectrum disorders, continuing antipsychotic treatment at standard doses or switching to a different antipsychotic are similar in prevention of relapse, according to a network meta-analysis.
In patients with schizophrenia-spectrum disorders, continuing antipsychotic treatment at standard doses or switching to a different antipsychotic are similar in prevention of relapse, according to a network meta-analysis.
In patients with...
09/28/2022
Psych Congress Network

Advertisement

Advertisement

Advertisement

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Advertisement

Advertisement

Sign Up

Psych Congress Network Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use